Primecap Management Co. CA Takes $4.64 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Key Points

• Primecap Management acquired 957,420 shares of Zentalis Pharmaceuticals in the second quarter, establishing a stake worth approximately $4.64 million, or 1.34% of the company. Other institutions, including BlackRock and Millennium Management, also increased their positions.
• ZNTL reported a quarterly loss of $0.59 per share, missing analyst expectations of a $0.49 loss. Analysts expect a full-year loss of $2.14 per share.
• The stock opened at $3.89, while analyst opinions remain mixed: the consensus rating is “Hold” with an average price target of $6.75, compared with recent buy targets ranging from $8 to $11.

Primecap Management Co. CA bought a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 957,420 shares of the company's stock, valued at approximately $4,643,000. Primecap Management Co. CA owned about 1.34% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZNTL. BlackRock Inc. bought a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $18,205,000. 5AM Venture Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 705.7% during the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company's stock worth $5,330,000 after acquiring an additional 3,457,913 shares during the period. Millennium Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after acquiring an additional 2,111,951 shares during the last quarter. Ishara Investments LP bought a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $1,782,000. Finally, Opaleye Management Inc. lifted its holdings in Zentalis Pharmaceuticals by 342.6% during the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company's stock valued at $1,891,000 after purchasing an additional 1,084,356 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $3.89 on Thursday. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $6.95. The stock has a market capitalization of $278.80 million, a price-to-earnings ratio of -1.99 and a beta of 1.92. The business's fifty day moving average price is $4.36 and its two-hundred day moving average price is $3.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). Research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on ZNTL. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an "outperform" rating and a $8.00 target price for the company. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a "buy" rating and a $11.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Finally, Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $6.75.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 4,335,000 shares of the business's stock in a transaction on Friday, August 14th. The stock was purchased at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the acquisition, the insider directly owned 17,844,973 shares of the company's stock, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.80% of the stock is owned by company insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source